Abstract
Anti-immunosuppressive drugs including cyclosporineA and cyclophosphamide have been used for the management of frequency relapse nephrotic syndrome (FRNS). However, there is the limitation of the usage of such agents because of the cytotoxic advers effects. Moreover long-time use of the same immunosuppressive agent may induce the tachyphylaxis. The aim of this study is to determine the efficacy and safety of mizoribine, a relatively newly developed immunosuppressive agent in Japan for the management of FRNS. Single divided of 5 mg/kg of mizoribin (max. 150 mg/day) was given to the patients at morning and serum concentration of this drug was measured 2 hours after administration. 22 patients with FRNS (relapse:9 and remission 13) were enrolled in this study. Their mean age (years)/mean body weight(kg)/mean mizoribine dose(mg/kg/day)/mean mizoribine serum concentration (μg/ml) was 17.1/49.5/3.23/1.56 and 9.8/27.9/4.63/2.93, respectively. This study may suggested that mizoribine is effective for the suppression of the relapse in patients with FRNS, especially in children below than 10 years and 30kg of body weight.
